Dr. Gail D’Onofrio, professor of emergency medicine and public health, and Dr. David Fiellin, professor of medicine, emergency medicine, and public health, are lead investigators in a $25.5 million study being conducted by the National Drug Abuse Treatment Clinical Trials Network’s New England Consortium Node (PIs: Dr. Roger Weiss, McLean Hospital/Harvard Medical School and Dr. Kathleen Carroll, Department of Psychiatry, Yale School of Medicine). The Emergency Department (ED)-Initiated buprenorphine Validation Network Trial (ED-INNOVATION) involves 30 diverse emergency departments (EDs) throughout the U.S.
The investigators will test an implementation strategy to guide the development of ED-initiated treatment of opioid use disorder with buprenorphine programs at the sites, and subsequently compare the effectiveness of two formulations of buprenorphine, sublingual versus an extended release 7-day injectable formulation in engaging ED patients with untreated opioid use disorder in medication treatment at 7 days. In addition, Dr. Andrew Taylor, assistant professor in emergency medicine, will lead a study developing and validating opioid use disorder phenotypes to better identify and characterize opioid use disorder in EDs. Other Yale investigators include Drs. Kathryn Hawk, James Dziura, Michael Pantalon, Arjun Venkatesh and Edouard Coupet from the Department of Emergency Medicine and Drs. Paul Joudrey, Jennifer Edelman and Patrick O’Connor from the Department of Medicine.Tags: Friday Letter Submission, Publish on October 18